Skip to content

A Study on the Effectiveness and Practicality of Identifying the First Lymph Nodes in Ovarian Cancer

Sentinel node Clinical Outcomes and Practical Evaluation in Ovarian Cancer - SCOPE Study

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs051250261
Enrollment
30
Registered
2026-03-27
Start date
2026-03-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer Ovarian cancer

Interventions

The procedure is initiated with a standard open or laparoscopic approach. Indocyanine green (ICG) is locally injected into the utero-ovarian ligament and the infundibulopelvic ligament. Using a near-i
D007208
Indocyanine Green

Sponsors

Amano Tsukuru
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Patients with stage I-IIA ovarian cancer for whom radical surgery including pelvic and para-aortic lymphadenectomy is indicated. 2. Histological subtype is not restricted. 3. Patients who, based on preoperative imaging (pelvic MRI, abdominal-pelvic CT, and/or PET/CT), show no evidence of peritoneal dissemination or distant metastasis, and no pathological lymphadenopathy (defined as short-axis diameter of 15 mm or more on CT or SUVmax of 2.5 or more on PET/CT). 4. Patients aged 18 years or older at the time of enrollment. 5. Patients with an ECOG Performance Status of 0 or 1. 6. Patients with laboratory test results within 56 days prior to enrollment that meet all of the following criteria: (1) White blood cell count of 3000/microL or more (2) Platelet count of 100000/microL or more (3) AST and ALT levels of 100 IU/L or less (4) Total bilirubin of 2.0 mg/dL or less (5) Serum creatinine of 1.5 mg/dL or less 7. Patients who have provided written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with a known hypersensitivity or prior adverse reaction to indocyanine green (ICG). 2. Patients with a history of iodine hypersensitivity. 3. Pregnant women, breastfeeding women, or patients who may be pregnant. 4. Patients deemed unsuitable for participation in this study at the discretion of the principal physician.

Design outcomes

Primary

MeasureTime frame
Sentinel lymph node detection rate using indocyanine green in ovarian cancer (detection of at least one SLN).

Secondary

MeasureTime frame
Location and number of identified sentinel lymph nodes (SLNs) SLN detection rate (ipsilateral pelvic), SLN detection rate (para-aortic) Presence or absence of metastasis in each SLN Concordance rate between intraoperative frozen-section diagnosis and final permanent pathological diagnosis of SLN biopsy Incidence of adverse events (adverse reactions)

Contacts

Public ContactTsukuru Amano

Shiga University of Medical Science

tsukuru@belle.shiga-med.ac.jp+81-77-548-2267

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026